LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform.
The last earnings update was 24 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
LogicBio Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
LogicBio Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LogicBio Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare LogicBio Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare LogicBio Therapeutics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare LogicBio Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if LogicBio Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if LogicBio Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
LogicBio Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
LogicBio Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
LogicBio Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
LogicBio Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
LogicBio Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
LogicBio Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Frederic Chereau, also known as Fred, is the President and Chief Executive Officer of LogicBio Therapeutics, Inc. since April 2016 and serves as its Director. He served as the President and Chief Operating Officer of aTyr Pharma Inc. from February 05, 2014 to July 13, 2015. Mr. Chereau served as Senior Vice President at Shire plc since September 2012, where he had worldwide strategic and financial responsibility for the overall franchise activities. Mr. Chereau served as Senior Vice President and Franchise Lead of Angioedema Franchise at Shire Human Genetic Therapies Inc., since September 2012. Mr. Chereau oversaw the development and execution of the global strategy for the angioedema franchise. He served as Chief Executive Officer and President of Pervasis Therapeutics, Inc. since October 2008, where he led it through key strategies for operational, business development portfolio and R&D refinement. Mr. Chereau served as Vice President and General Manager of Genzyme Cardiovascular (CV), a business unit within Genzyme Corporation in Cambridge. He was responsible for launching and commercializing a hypercholesterolemia product (Cholestagel(R) - colesevelam) outside of the US and oversaw late clinical stage gene therapy program in Peripheral Arterial Disease and various stage programs. He also led Genzyme's cardiovascular business development activities, including and its in-licensing transaction with ISIS Pharmaceuticals. Mr. Chereau held various positions within Genzyme in Europe and in the US culminating in his position at Genzyme CV since 2006. He also served as the Chief Operating Officer of MG Biotherapeutics LLC, a Genzyme and Medtronic joint-venture formed to develop cellular therapies for cardiac repair. He held sales and marketing positions at a French medical device retail company in the hemodialysis field. He began his career with Hemotech in France where he held various sales and marketing positions. Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility initially within Genzyme France and Genzyme Europe. He serves as a Director of Pervasis Therapeutics, Inc. He is a Member of the Board of Directors of the French American Chamber of Commerce of New England and a Member of Strategic Advisory Board of the La Rochelle Business School. He is fluent in both French and English. Mr. Chereau holds a Bachelor's degree in Physics from Paris University, completed Master's Degree in Business Administration at the La Rochelle Business School, and received Executive MBA from INSEAD.
Insufficient data for Fred to compare compensation growth.
Fred's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the LogicBio Therapeutics management team is less than 2 years, this suggests a new team.
Chief Financial Officer
Chief Business Officer
Vice President of Technology Development
Chief Scientific Officer
Senior VP & Head of Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the LogicBio Therapeutics board of directors is less than 3 years, this suggests a new board.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.